Review of high dose vancomycin in the treatment of Clostridioides difficile infection

References

• Guh AY, Mu Y, Winston LG, et al. Trends in U.S. burden of Clostridioides difficile infection and outcomes. N Engl J Med. 2020;382(14):1320–1330.
   PubMed Web of Science ®Google Scholar
• Bagdasarian N, Rao K, Malani PN. Diagnosis and treatment of Clostridium difficile in adults: a systematic review. JAMA. 2015;313(4):398–408.
   PubMed Web of Science ®Google Scholar
• Ooijevaar RE, van Beurden YH, Terveer EM, et al. Update of treatment algorithms for Clostridium difficile infection. Clin Microbiol Infect. 2018;24(5):452–462.
   PubMed Web of Science ®Google Scholar
• Nelson RL, Suda KJ, Evans CT. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults. Cochrane Database Syst Rev. 2017;3:CD004610.
   PubMed Web of Science ®Google Scholar
• McDonald LC, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):e1–e48.
   PubMed Web of Science ®Google Scholar
• Brouwer DM, Corallo CE, Coutsouvelis J. Systemic absorption of low-dose oral vancomycin. J Pharm Pract Res. 2005;35(3):222–223.
   Google Scholar
• Lucas RA, Bowtle WJ, Ryden R. Disposition of vancomycin in healthy volunteers from oral solution and semisolid matrix capsules. J Clin Pharm Ther. 1987;12:27–31.
   PubMed Web of Science ®Google Scholar
• Snydman DR, McDermott LA, Thorpe CM, et al. Antimicrobial susceptibility and ribotypes of Clostridium difficile isolates from a Phase 2 clinical trial of ridinilazole (SMT19969) and vancomycin. J Antimicrob Chemother. 2018;73(8):2078–2084.
   PubMed Web of Science ®Google Scholar
• Karlowsky JA, Adam HJ, Kosowan T, et al. PCR ribotyping and antimicrobial susceptibility testing of isolates of Clostridium difficile cultured from toxin-positive diarrheal stools of patients receiving medical care in Canadian hospitals: the Canadian Clostridium difficile Surveillance Study (CAN-DIFF) 2013-2015. Diagn Microbiol Infect Dis. 2018;91(2):105–111.
   PubMed Web of Science ®Google Scholar
• Gonzales M, Pepin J, Frost EH, et al. Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection. BMC Infect Dis. 2010;10:363.
   PubMed Web of Science ®Google Scholar
• Thabit AK, Nicolau DP. Impact of vancomycin faecal concentrations on clinical and microbiological outcomes in Clostridium difficile infection. Int J Antimicrob Agents. 2015;46(2):205–208.
   PubMed Web of Science ®Google Scholar
• Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108(4):478–498.
   PubMed Web of Science ®Google Scholar
• Debast SB, Bauer MP, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014;20(2):1–26.
   PubMed Web of Science ®Google Scholar
• Trubiano JA, Cheng AC, Korman TM, et al. Australasian Society of Infectious Diseases updated guidelines for the management of Clostridium difficile infection in adults and children in Australia and New Zealand. Intern Med J. 2016;46(4):479–493.
   PubMed Web of Science ®Google Scholar
• Loo V, Davis I, Embil J, et al. Association of medical microbiology and infectious disease Canada treatment practice guidelines for Clostridium difficile infection. JAMMI. 2018;3(2):71–92.
   Google Scholar
• Sartelli M, Di Bella S, McFarland LV, et al. 2019 update of the WSES guidelines for management of Clostridioides (Clostridium) difficile infection in surgical patients. World J Emerg Surg. 2019;14:8.
   PubMed Web of Science ®Google Scholar
• Fekety R, Silva J, Kauffman C, et al. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med. 1989;86(1):15–19.
   PubMed Web of Science ®Google Scholar
• McFarland LV, Surawicz CM, Rubin M, et al. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol. 1999;20(1):43–50.
   PubMed Web of Science ®Google Scholar
• Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis. 2000;31(4):1012–1017.
   PubMed Web of Science ®Google Scholar
• Lam SW, Bass SN, Neuner EA, et al. Effect of vancomycin dose on treatment outcomes in severe Clostridium difficile infection. Int J Antimicrob Agents. 2013;42(6):553–558.
   PubMed Web of Science ®Google Scholar
• Bouza E, Alcalá L, Marín M, et al. An outbreak of Clostridium difficile PCR ribotype 027 in Spain: risk factors for recurrence and a novel treatment strategy. Eur J Clin Microbiol Infect Dis. 2017;36(10):1777–1786.
   PubMed Web of Science ®Google Scholar
• Cunha BA, Sessa J, Blum S. Enhanced efficacy of high dose oral vancomycin therapy in Clostridium difficile diarrhea for hospitalized adults not responsive to conventional oral vancomycin therapy: antibiotic stewardship implications. JCM. 2018;7(4):75.
   Google Scholar
• McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo- controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA. 1994;271(24):1913–1918.
   PubMed Web of Science ®Google Scholar
• Neal MD, Alverdy JC, Hall DE, et al. Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. Ann Surg. 2011;254(3):423–427.
   PubMed Web of Science ®Google Scholar
• Malamood M, Nellis E, Ehrlich AC, et al. Vancomycin enemas as adjunctive therapy for Clostridium difficile infection. J Clin Med Res. 2015;7(6):422–427.
   PubMedGoogle Scholar
• Akamine CM, Ing MB, Jackson CS, et al. The efficacy of intracolonic vancomycin for severe Clostridium difficile colitis: a case series. BMC Infect Dis. 2016;16:316.
   PubMed Web of Science ®Google Scholar
• Feeney ME, Thompson M, Gerlach AT, et al. Evaluation of rectal vancomycin irrigation for treatment of Clostridioides difficile infection in patients post-colectomy for toxic colitis. Surg Infect. 2019;20(5):411–415.
   PubMed Web of Science ®Google Scholar
• Olson MM, Shanholtzer CJ, Lee JT, Jr, et al. Ten years of prospective Clostridium difficile associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982 – 1991. Infect Control Hosp Epidemiol. 1994;15(6):371–381.
   PubMed Web of Science ®Google Scholar
• Shetler K, Nieuwenhuis R, Wren SM, et al. Decompressive colonoscopy with intracolonic vancomycin administration for the treatment of severe pseudomembranous colitis. Surg Endosc. 2001;15(7):653–659.
   PubMed Web of Science ®Google Scholar
• Apisarnthanarak A, Razavi B, Mundy LM. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis. 2002;35(6):690–696.
   PubMed Web of Science ®Google Scholar
• Kim PK, Huh HC, Cohen HW, et al. Intracolonic vancomycin for severe Clostridium difficile colitis. Surg Infect. 2013;14(6):532–539.
   PubMed Web of Science ®Google Scholar
• Saffouri G, Khanna S, Estes L, et al. Outcomes from rectal vancomycin therapy in patients with Clostridium difficile infection. Am J Gastroenterol. 2014;109(6):924–925.
   PubMed Web of Science ®Google Scholar
• Wilke K, Helbig S, de With K. Serum vancomycin concentrations after oral and intracolonic vancomycin administration in a patient with colonic discontinuity and severe Clostridium difficile infection. Am J Health Syst Pharm. 2018;75(9):e189–e193.
   PubMed Web of Science ®Google Scholar
• Hirata S, Matoba M, Izumi S, et al. Elevated serum vancomycin concentrations after oral administration in a hemodialysis patient with pseudomembranous colitis. J Clin Pharmacol Ther. 2003;7:11–23.
   Google Scholar
• Coutsouvelis J, Witney K, Corallo C, et al. Systemic absorption from oral vancomycin: check the dose! J Pharm Pract Res . 2011;41(3):225–226.
   Google Scholar
• Pogue JM, Depestel DD, Kaul DR, et al. Systemic absorption of oral vancomycin in a peripheral blood stem cell transplant patient with severe graft-versus-host disease of the gastrointestinal tract. Transpl Infect Dis. 2009;11(5):467–470.
   PubMed Web of Science ®Google Scholar
• Pettit NN, Depestel DD, Fohl AL, et al. Risk factors for systemic vancomycin exposure following administration of oral vancomycin for the treatment of Clostridium difficile infection. Pharmacotherapy. 2015;35(2):119–126.
   PubMed Web of Science ®Google Scholar
• Al-Nassir WN, Sethi AK, Li Y, et al. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin- resistant enterococci during treatment of Clostridium difficile-associated disease. AAC. 2008;52(7):2403–2406.
   Google Scholar
• Nerandzic MM, Mullane K, Miller MA, et al. Reduced acquisition and overgrowth of vancomycin-resistant Enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clin Infect Dis. 2012;55(2):S121–S126.
   PubMedGoogle Scholar
• Falcone M, Russo A, Iraci F, et al. Risk factors and outcomes for bloodstream infections secondary to Clostridium difficile infection. Antimicrob Agents Chemother. 2016;60(1):252–257.
   PubMed Web of Science ®Google Scholar
• Patel I, Wungjiranirun M, Theethira T, et al. Lack of adherence to SHEA-IDSA treatment guidelines for Clostridium difficile infection is associated with increased mortality. J Antimicrob Chemother. 2017;72(2):574–581.
   PubMed Web of Science ®Google Scholar
• Wieczorkiewicz S, Zatarski R. Adherence to and outcomes associated with a Clostridium difficile guideline at a large teaching institution. Hosp Pharm. 2015;50(1):042–050.
   PubMedGoogle Scholar
• Curtin BF, Zarbalian Y, Flasar MH, et al. Clostridium difficile-associated disease: adherence with current guidelines at a tertiary medical center. WJG. 2013;19(46):8647–8651.
   PubMed Web of Science ®Google Scholar
• Crowell KT, Julian KG, Katzman M, et al. Compliance with Clostridium difficile treatment guidelines: effect on patient outcomes. Epidemiol Infect. 2017;145(11):2185–2192.
   PubMed Web of Science ®Google Scholar
• Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431–455.
   PubMed Web of Science ®Google Scholar